Identification of common genetic variants in KCNQ family genes associated with gastric cancer survival in a Chinese population

Abstract

The KCNQ family of genes (KCNQ1-KCNQ5), encoding voltage-gated K⁺ (Kv) channels, have been demonstrated to play potential pathophysiological roles in cancers. However, the associations between genetic variants located in KCNQ family genes and gastric cancer survival remain unclear. In this study, a large-scale cohort comprising 1135 Chinese gastric cancer patients was enrolled to identify genetic variants in KCNQ family genes associated with overall survival (OS). Based on the survival evaluation of all five KCNQ family genes, KCNQ1 was selected for subsequent genetic analysis. In both Cox regression model and stepwise Cox regression model used to evaluate survival-related genetic variants, we found that KCNQ1 rs10832417G>T was associated with an increased OS in gastric cancer patients (adjusted hazards ratio [HR] = 0.84, 95% confidence interval [CI]: 0.72-0.98, P = 0.023). Subsequently, a nomogram was constructed to enhance the prognostic capacity and clinical translation of rs10832417 variants. The rs10832417 T allele was predicted to increase the minimum free energy of the secondary structure. Furthermore, we observed that gastric cancer patients with downregulated KCNQ1 expression had a poorer survival across multiple public datasets. The findings of the present study indicate that KCNQ1 rs10832417 may serve as an independent prognostic predictor of gastric cancer, providing novel insights into the progression and survival of the disease.

Keywords

gastric cancer / survival / genetic variants / ionic channels

Fundings

This present work was supported by grants from the National Natural Science Foundation of China (Grant No. 82273458 to Jinfei Chen) and the Start-up Fund for the Recruited Talents of the First Affiliated Hospital of Wenzhou Medical University (Grant No. 2021QD025 to Jinfei Chen).

Acknowledgments

None.

References

[1] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648. doi: 10.1016/S0140-6736(20)31288-5

[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660

[3] Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives[J]. Semin Cancer Biol, 2018, 51: 36-49. doi: 10.1016/j.semcancer.2017.12.004

[4] Ajani JA, Lee J, Sano T, et al. Gastric adenocarcinoma[J]. Nat Rev Dis Primers, 2017, 3(1): 17036. doi: 10.1038/nrdp.2017.36

[5] Barrese V, Stott JB, Greenwood IA. KCNQ-encoded potassium channels as therapeutic targets[J]. Annu Rev Pharmacol Toxicol, 2018, 58: 625-648. doi: 10.1146/annurev-pharmtox-010617-052912

[6] Mondejar-Parreño G, Perez-Vizcaino F, Cogolludo A. Kv7 channels in lung diseases[J]. Front Physiol, 2020, 11: 634. doi: 10.3389/fphys.2020.00634

[7] Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease[J]. Nat Rev Neurosci, 2000, 1(1): 21-30. doi: 10.1038/35036198

[8] Robbins J. KCNQ potassium channels: physiology, pathophysiology, and pharmacology[J]. Pharmacol Ther, 2001, 90(1): 1-19. doi: 10.1016/S0163-7258(01)00116-4

[9] Huang C, Li J, Zhang X, et al. The miR-140-5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma[J]. FASEB J, 2020, 34(8): 10623-10639. doi: 10.1096/fj.202000088RR

[10] Ling J, Erol F, Viatchenko-Karpinski V, et al. Orofacial neuropathic pain induced by oxaliplatin: downregulation of KCNQ2 channels in V2 trigeminal ganglion neurons and treatment by the KCNQ2 channel potentiator retigabine[J]. Mol Pain, 2017, 13: 1744806917724715.

[11] Zhou X, Wei J, Song M, et al. Novel role of KCNQ2/3 channels in regulating neuronal cell viability[J]. Cell Death Differ, 2011, 18(3): 493-505. doi: 10.1038/cdd.2010.120

[12] Zhang Y, Mei H, Xu K, et al. Associations between KCNQ1 and ITIH4 gene polymorphisms and infant weight gain in early life[J]. Pediatr Res, 2022, 91(5): 1290-1295. doi: 10.1038/s41390-021-01601-8

[13] Zhang W, Wang H, Guan X, et al. Variant rs2237892 of KCNQ1 is potentially associated with hypertension and macrovascular complications in type 2 diabetes mellitus in a Chinese Han population[J]. Genomics Proteomics Bioinformatics, 2015, 13(6): 364-370. doi: 10.1016/j.gpb.2015.05.004

[14] Takahashi H, Sai K, Saito Y, et al. Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect[J]. PLoS One, 2014, 9(8): e105160. doi: 10.1371/journal.pone.0105160

[15] Van Laer L, Carlsson PI, Ottschytsch N, et al. The contribution of genes involved in potassium-recycling in the inner ear to noise-induced hearing loss[J]. Hum Mutat, 2006, 27(8): 786-795. doi: 10.1002/humu.20360

[16] Pawelczyk M, Van Laer L, Fransen E, et al. Analysis of gene polymorphisms associated with K⁺ ion circulation in the inner ear of patients susceptible and resistant to noise-induced hearing loss[J]. Ann Hum Genet, 2009, 73(4): 411-421. doi: 10.1111/j.1469-1809.2009.00521.x

[17] Gong Y, Zhao W, Jia Q, et al. IKBKB rs2272736 is associated with gastric cancer survival[J]. Pharmgenomics Pers Med, 2020, 13: 345-352. doi: 10.2147/PGPM.S258761

[18] Yang J, Wei X, Wu Q, et al. Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer[J]. Mol Med Rep, 2011, 4(6): 1139-1143. https://www.spandidos-publications.com/mmr/4/6/1139

[19] Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape[J]. Genome Biol, 2017, 18(1): 220. doi: 10.1186/s13059-017-1349-1

[20] Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514. doi: 10.1093/nar/gkaa407

[21] Thompson E, Eldstrom J, Fedida D. Hormonal signaling actions on Kv7.1 (KCNQ1) channels[J]. Annu Rev Pharmacol Toxicol, 2021, 61: 381-400. doi: 10.1146/annurev-pharmtox-010919-023645

[22] Den Uil SH, Coupé VMH, Linnekamp JF, et al. Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence[J]. Br J Cancer, 2016, 115(12): 1565-1574. doi: 10.1038/bjc.2016.376

[23] Than BLN, Goos JACM, Sarver AL, et al. The role of KCNQ1 in mouse and human gastrointestinal cancers[J]. Oncogene, 2014, 33(29): 3861-3868. doi: 10.1038/onc.2013.350

[24] Fan H, Zhang M, Liu W. Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2018, 503(4): 3100-3107. doi: 10.1016/j.bbrc.2018.08.099

[25] Gaulton KJ, Ferreira T, Lee Y, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci[J]. Nat Genet, 2015, 47(12): 1415-1425. doi: 10.1038/ng.3437

[26] Hu F, Zhang Y, Qin P, et al. Integrated analysis of probability of type 2 diabetes mellitus with polymorphisms and methylation of KCNQ1 gene: a nested case-control study[J]. J Diabetes, 2021, 13(12): 975-986. doi: 10.1111/1753-0407.13212

[27] Lacaze P, Sebra R, Riaz M, et al. Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent[J]. npj Genom Med, 2021, 6(1): 51. doi: 10.1038/s41525-021-00211-x

[28] Li C, Li Z, Liu S, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese[J]. Nat Commun, 2015, 6(1): 7041. doi: 10.1038/ncomms8041

[29] Kuruma S, Egawa N, Kurata M, et al. Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan[J]. World J Gastroenterol, 2014, 20(46): 17456. doi: 10.3748/wjg.v20.i46.17456

[30] Liu X, Chen Z, Zhao X, et al. Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen[J]. Pharmacogenomics, 2015, 16(9): 959-970. doi: 10.2217/pgs.15.49

[31] Yang Z, Yuan L, Yang L, et al. Association study between KCNQ1 and KCNQ1OT1 genetic polymorphisms and gastric cancer susceptibility and survival in a Chinese Han population: a case-control study[J]. Ann Transl Med, 2021, 9(2): 156. doi: 10.21037/atm-20-8052

[32] Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation[J]. Science, 2003, 299(5604): 251-254. doi: 10.1126/science.1077771

[33] Goldenberg I, Zareba W, Moss AJ. Long QT syndrome[J]. Curr Probl Cardiol, 2008, 33(11): 629-694. doi: 10.1016/j.cpcardiol.2008.07.002

[34] Huang H, Kuenze G, Smith JA, et al. Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations[J]. Sci Adv, 2018, 4(3): eaar2631. doi: 10.1126/sciadv.aar2631

[35] Chen K, Yang D, Li X, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy[J]. Proc Natl Acad Sci U S A, 2015, 112(4): 1107-1112. doi: 10.1073/pnas.1422640112

[36] Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines[J]. Lancet Oncol, 2020, 21(8): e386-e397. doi: 10.1016/S1470-2045(20)30219-9